Equity · Healthcare
CYTK
Cytokinetics, Incorporated · NasdaqGS
The line runs $77 on 22 May through $81 on 24 July, on a scale from $60 to $90. Days the market did not trade hold the previous close, flat.
The chart above plots the price of CYTK over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 43 sessions over that window: $77 on 22 May 2026 through $81 on 24 July 2026.
Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Aug 19, 2026
CYTK insider trades
Showing the 12 most recent of 19 open-market trades in this window. The figures above count all of them.
Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.
Showing the 12 most recent of 29 compensation filings in this window. The figures above count all of them.
CYTK reported financials
CYTK reported revenue of $88.0M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$785.0M.
Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
CYTK earnings
no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
CYTK institutional holders
12 of the 45 institutional funds we track reported a CYTK position for the quarter ended 30 Jun 2026 — a combined $519.1M; the latest of those filings landed 14 Aug 2026.
Showing the 10 largest of 12 reported positions. The figures above count all of them.
Source: SEC EDGAR 13F filings
CYTK fails-to-deliver
On 23 Jul 2026, 341 shares of CYTK failed to deliver (about $28K).
Source: SEC fails-to-deliver (CNS) data
Congressional trades in CYTK
The most recent congressional trade disclosed in CYTK is a purchase by Gilbert Ray Cisneros, Jr. (house, CA), dated 30 Jun 2026.
Source: U.S. House of Representatives financial disclosures